Market News

Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.

Company hopes to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry.

The partnership will focus on rings for the administration of existing approved drugs, improving drug effectiveness and patient compliance.

Increasing appetite for digitised manufacturing and using data to improve GMP manufacturing.

Medicines regulators of the UK and Russian set out key principles to support their collaboration on improving public health.

Clients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product.

B2B Cosmetics will contribute their Emuage technology, which has received the “Innovation Award” at the trade show Consumer Electronics Show (CES) in Las Vegas.

New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

The new Irish facility will allow the company to continue to act as a gateway to Europe for its British and North American customers.

Company's VERIFI smart monitoring hub allows production teams to manage and maintain their containment solution which, in turn, helps assure operator safety and sterility assurance related performance during pharmaceutical manufacturing processes.

The first completed bio-banks will be used to develop more cost-effective, safe and efficacious cancer treatments.

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.

Fuels growth and biosimilar development in a fast-growing market.

Flexsafe RM TX bags enable reliable process performance for optimal cell growth.

Approval of generic vigabatrin tablets granted to Teva Pharmaceuticals USA.

The LyoS 2.0 control system software is fully configurable and fully validatable for regulated pharmaceutical and biotechnology applications.

New active ingredients coming from the research of BASF’s innovation platforms on epigenetics, microbiome and extraction.

The $4-million investment will be used to expand topical dosage formulation development services and innovative performance testing on topical and transdermal pharmaceutical products.

The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Web-based platform provides broad access to the first-ever cloud laboratory to integrate automated biology and chemistry research capabilities in a closed-loop system.

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

ELRIG UK and British Pharmacological Society initiate a 2-year strategic alliance.

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Tear Film's iLux Device offers innovative, customizable treatment for Meibomian Gland Dysfunction, a leading cause of dry eye.

The CoE showcases the latest end-to-end technological solutions for biomanufacturing.

Croda will not only gain ownership to Biosector’s rich development pipeline but will become the only adjuvant supplier in the world with an aseptic and GMP-certified manufacturing site for vaccine adjuvants.

Enhances company's capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells for wide range of diseases on a global scale.

Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

The €3.5 million investment in equipment, facilities and expert staff will significantly increase the capabilities at the site to match increasing demand and shorten processes for pharmaceutical clients.

Altered peptides from a South American wasp’s venom can kill bacteria but are nontoxic to human cells.

Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

The financing will power the global commercial launch of the company's Fluidity One system.

Main drivers cited as ‘high-growth domestic market’ and ‘expanding manufacturing exports’.

The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

Closing of sale to Procter & Gamble at a cash purchase price of €3.4 billion completed.

Zenith Technology survey reveals that more than half of those surveyed believe that Industry 4.0 will drive the most change.

The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

Company provided with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next 5 years.

Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

Cobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.

Products containing Erdosteine from Recipharm are now marketed in over 40 countries across the world and is available in four different dosage forms.

Patients could receive faster treatment following boost to streamline the production of medicines and treatments.

Extra funding for strategic move into downstream formulation and fill finish capabilities and full exploitation of Lock-Release as new ADC manufacturing paradigm.

Company has successfully developed and validated impurity test methods in line with ICH Q3D regulatory guidelines.

Sartorius Stedim Biotech will continue to offer Lonza media and buffer products but under a non-exclusive agreement.

Wax-based and readily biodegradable: Euperlan OP White and Cegesoft Peel.

Event sees more innovation centralising at the Paris hub with entries for the awards and Start-up Hub opening.

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Trainees are provided with real-world examples of process workflows.

Larger headquarters will enable the company to free up space for additional laboratories and further expand capabilities.

Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries.

Company's manufacturing building for laboratory instruments in Göttingen wins the Global Excellence in Operations Award.

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

BioProduction’s content platform will be added to the bioLIVE exhibition, creating one of the world’s largest event hubs for the bio industry.

Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.

Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.

Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies.

With only a month to go, it really is too late to start trying to develop an in-house solution.

OPTi-OX technology allows the company to produce human cells of unprecedented quality, purity, and consistency.

Restriction due to potential cross-contamination.

Eight of the top ten pharma nations reporting improving market conditions.

CF3 coupled with UV-Vis detection able to separate and quantify the amount of free drug in a liposome-drug product.

‘One Site Shop’ expands to respond to growing demands.

BioVyon range have been incorporated into products to achieve more sensitive analysis, better healthcare, improved medical knowledge and faster diagnosis and treatment of diseases.

The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

The virtual platform is designed to allow the healthcare industry to effectively research and explore new technologies that will help to shape the future of the pharmaceutical supply chain.

Mylan achieves key milestone to provide US diabetes patients with more affordable generic version of Sanofi's Lantus insulin glargine vials.

New facility will offer customers the full range of services from development through to commercial-scale manufacturing

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

CMOs hit by reduced volumes of opioid manufacturing from DEA quota changes, but cannabis sales to ignite.

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

Therapeutic ADC market expected to reach $4 billion by 2023.

The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.

Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

Companies new to CPHI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

Greater product protection thanks to reliable sealing technologies.

The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.

Idifarma's GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.

Smaller bioreactors and high-density perfusion techniques needed as manufacturing makes significant efficiency improvements.

Facility to focus on developing and manufacturing the company's biosimilar portfolio.

Encorafenib in combination with binimetinib demonstrated 14.9 months median progression-free survival compared with vemurafenib monotherapy (7.3 months).

Lonza expansion includes drug substance development, and drug substance and drug product manufacturing.

GARDair removes the need for animal testing and opens a completely new market.

Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

The new services will focus on quality control analysis and stability testing of biopharmaceuticals.

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.

Faster GMP incident response and resolution times when manufacturing IT applications fail or are not running to their optimum capacity.

Customers to benefit from simplified, scalable solutions for intensified cell culture.

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.

Secure data sharing across the pharmaceutical industry.

New facility to carry out EU release testing ensuring continuous supply for customers regardless of the outcome of Brexit negotiations.

Life Science Factory gGmbH offers labs, co-working spaces and consulting services for life science entrepreneurs.

SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.

CPHI Annual Report expert sees CDMOs as potentially a source of process innovation but warns both regulator and license holders need to move past regulatory diktats.

Investment will triple Sharp’s clinical service capacity for the pharmaceutical, biotech and clinical research sectors.

Leading antibiotics manufacturer reduces unacceptable levels of production downtime.

C-CIT Sensors launches its innovative and easy-to-handle single-use wireless bi-parametric metabolic monitoring system.

Investment will fuel the digitalization of the global pharmaceutical supply chain through the integration of real-time information-sharing, to create a highly predictable supply chain for the industry.

With only 6 months left in which to become EU FMD-compliant, how can companies make the best use of their now limited options?

The company’s engagement in Corporate Social Responsibility includes reducing consumption of water in manufacturing by using innovative technologies.

CPHI Middle East & Africa opens in Abu Dhabi as finished dosage formulations expand quickly, driven by government reforms to further increase local manufacturing.

Company's multimillion pound purpose-built facility becomes fully operational amidst growing interest worldwide in its potentially game-changing plant transient expression technology, Hypertrans.

Now less than a year away from when the UK officially leaves the EU, the main goal remains the same - maintaining access to new drugs for patient health.

Tadalafil is indicated in the treatment of pulmonary arterial hypertension to improve exercise ability.

New service to reliably and reproducibly isolate exosomes from almost any biofluid.